Br J Clin Pharmacol. 2020 Aug 1. doi: 10.1111/bcp.14501. Online ahead of print.
AIM: To determine whether enzyme-inducing antiseizure drugs (ASDs) affect the risk of developing COPD or lung cancer in smokers.
METHODS: Cases of COPD and lung cancer and matched controls without these conditions were identified from a population of smokers with ≥ 1 prescription for any type of ASD in the Clinical Practice Research Datalink UK database of patients managed in primary care (1995 - 2016). A matched case-control study was performed utilising multivariate logistic regression analyses of exposure to enzyme-inducing ASDs compared to non enzyme-inducing ASDs. The duration of ASD exposure and level of tobacco exposure were also assessed.
RESULTS: We identified 5952 incident COPD and 1373 incident lung cancer cases, and 59 328 and 13 681 matched controls, respectively. Compared with never use, ever use of enzyme-inducing ASDs was associated with slightly decreased risk estimates of COPD (adjusted odds ratio [aOR]: 0.85, 95% CI: 0.81-0.89) and lung cancer (aOR: 0.82, 95% CI: 0.73-0.92). These risk estimates were attenuated in heavy smokers.
CONCLUSIONS: We found slightly decreased risk estimates of COPD and lung cancer among light smokers taking enzyme-inducing ASDs and hypothesise that this may be related to induction of detoxification of tobacco-specific lung toxins.